---
title: "JOINN Laboratories Grants New Three-Year H-Share Awards to Management"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284780987.md"
description: "JOINN Laboratories (China) Co., Ltd. has granted 1,430,000 H-share awards to 12 selected participants, representing 1.20% of its issued H shares. The awards, priced at nil, will vest over three years based on performance indicators. This initiative aims to align management with shareholders and enhance long-term performance. The current analyst rating for JOINN Laboratories (HK:6127) is a Hold, with a price target of HK$16.30. The company specializes in preclinical research services and has a market cap of HK$30.67B."
datetime: "2026-04-30T13:05:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284780987.md)
  - [en](https://longbridge.com/en/news/284780987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284780987.md)
---

# JOINN Laboratories Grants New Three-Year H-Share Awards to Management

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) is now available.

JOINN Laboratories (China) Co., Ltd. has granted 1,430,000 H-share awards, equal to about 1.20% of its issued H shares and 0.191% of total share capital, to 12 selected participants under its existing share incentive scheme. The grant, which includes several company directors, is priced at nil and will be settled using existing shares previously acquired on-market by a trustee.

The award shares will vest in three tranches over three years, with 40% vesting on the first and second anniversaries of the grant date and 20% on the third, subject to performance indicators and other vesting conditions. This structured equity incentive is designed to strengthen management alignment with shareholders, potentially enhancing long-term performance and signaling confidence in the company’s future prospects to investors.

The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.

**More about JOINN Laboratories (China) Co., Ltd. Class H**

JOINN Laboratories (China) Co., Ltd. is a China-based life sciences company listed in Hong Kong, engaged in preclinical and related research services for pharmaceutical and biotech clients. Its H shares trade on the Stock Exchange of Hong Kong, giving it access to international capital and aligning management incentives with public market performance.

**Average Trading Volume:** 3,946,333

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$30.67B

For a thorough assessment of 6127 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [603127.CN](https://longbridge.com/en/quote/603127.CN.md)
- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)

## Related News & Research

- [Artivion Completes Acquisition of Endospan Ltd. | AORT Stock News](https://longbridge.com/en/news/286758893.md)
- [Micware Co., Ltd. Announces Closing of Upsized Initial Public Offering | MWC Stock News](https://longbridge.com/en/news/286607672.md)
- [Prabhudas Lilladher Keeps Their Buy Rating on Chalet Hotels Ltd. (CHALET)](https://longbridge.com/en/news/286845152.md)
- [Shaw and Partners Keeps Their Buy Rating on Southern Cross Gold Consolidated Ltd. Chees Depository Interest Repr 1 shs (SX2)](https://longbridge.com/en/news/286979340.md)
- [Earnings Beat: Odfjell Drilling Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286515920.md)